Patient characteristics
. | N = 170 . | % or range . |
---|---|---|
Age, y | ||
Median | 66 | 20-83 |
18-60 | 33 | 19 |
>60 | 137 | 81 |
Sex | ||
Male | 80 | 47 |
Female | 90 | 53 |
AML subtype | ||
MRC-AML | 117 | 69 |
t-AML | 48 | 28 |
Others∗ | 5 | 3 |
Median no. of WBC, G/L | 3 | 0-213 |
Hyperleukocytosis | 16 | 9 |
Karyotype | ||
Complex | 51 | 30 |
Monosomal | 32 | 19 |
2017 ELN genetic risk stratification | ||
Favorable | 8 | 5 |
Intermediate | 61 | 36 |
Adverse | 98 | 58 |
2022 ELN genetic risk stratification | ||
Favorable | 8 | 5 |
Intermediate | 16 | 9 |
Adverse | 143 | 84 |
Lindsley classifier (N = 107) | ||
de novo/pan-AML | 30 | 28 |
Secondary-type mutations AML | 42 | 39 |
TP53-mutated AML | 35 | 33 |
. | N = 170 . | % or range . |
---|---|---|
Age, y | ||
Median | 66 | 20-83 |
18-60 | 33 | 19 |
>60 | 137 | 81 |
Sex | ||
Male | 80 | 47 |
Female | 90 | 53 |
AML subtype | ||
MRC-AML | 117 | 69 |
t-AML | 48 | 28 |
Others∗ | 5 | 3 |
Median no. of WBC, G/L | 3 | 0-213 |
Hyperleukocytosis | 16 | 9 |
Karyotype | ||
Complex | 51 | 30 |
Monosomal | 32 | 19 |
2017 ELN genetic risk stratification | ||
Favorable | 8 | 5 |
Intermediate | 61 | 36 |
Adverse | 98 | 58 |
2022 ELN genetic risk stratification | ||
Favorable | 8 | 5 |
Intermediate | 16 | 9 |
Adverse | 143 | 84 |
Lindsley classifier (N = 107) | ||
de novo/pan-AML | 30 | 28 |
Secondary-type mutations AML | 42 | 39 |
TP53-mutated AML | 35 | 33 |
WBC, white blood cell.